Daxor Expands Outpatient Cardiology Footprint with Tennessee BVA Program
Event summary
- Daxor launched a new Blood Volume Analysis (BVA) diagnostic program at a healthcare facility in Southern Middle Tennessee on February 24, 2026.
- The program leverages Daxor’s ezBVA Lab for 98% accurate diagnostics with a 24-hour turnaround time.
- No capital investment required for the facility, as Daxor’s ezBVA Lab service is reimbursable.
- Michael Feldschuh, Daxor CEO, emphasized the role of precise volume assessment in improving patient outcomes and reducing healthcare costs.
The big picture
Daxor’s expansion into outpatient cardiology aligns with broader trends in value-based healthcare, where precise diagnostics are critical for managing chronic conditions like heart failure. The company’s ability to offer high-accuracy diagnostics without capital investment could accelerate adoption in cost-sensitive healthcare markets. This move also positions Daxor to compete more directly with traditional lab-based diagnostic providers.
What we're watching
- Market Expansion
- The pace at which Daxor can replicate this model in other high-volume outpatient settings.
- Reimbursement Dynamics
- Whether the reimbursement model for ezBVA Lab can sustain further adoption without capital investment.
- Clinical Adoption
- How quickly clinicians in the region integrate BVA diagnostics into standard outpatient cardiology protocols.
Related topics